We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

In this section

Shares

Syncona investment sells cancer study assets to AstraZeneca for $12m

Fri 27 December 2024 07:03 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Life science investor Syncona said its investment Achilles Therapeutics has sold cancer study assets to AstraZeneca for $12m (9.58m).

The deal involves transferring of the commercial license of data and samples from Achilles' TRACERx non-small cell lung cancer study to AstraZeneca, including samples and data.

Achilles added that it intended to cut an unspecified number of jobs and reduce the size of its board of directors.

Completion of this transaction signals the conclusion of the strategic review which was announced in September 2024.

Reporting by Frank Prenesti for Sharecast.com

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More company news from ShareCast